Comparative Pharmacology
Head-to-head clinical analysis: MULTIFUGE versus MVC PLUS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MULTIFUGE versus MVC PLUS.
MULTIFUGE vs MVC PLUS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multifuge is a combination product containing an antihistamine and a decongestant. The antihistamine (chlorpheniramine) competitively antagonizes histamine H1 receptors, reducing allergic symptoms. The decongestant (pseudoephedrine) stimulates alpha-adrenergic receptors, causing vasoconstriction and reducing nasal congestion.
MVC PLUS is a fixed-dose combination of maraviroc, a CCR5 co-receptor antagonist, and lamivudine, a nucleoside reverse transcriptase inhibitor. Maraviroc binds to CCR5 on CD4+ T cells blocking HIV-1 entry; lamivudine inhibits HIV reverse transcriptase via competitive inhibition and chain termination.
IV: 10 mg/kg body weight as a single dose; repeated every 48 hours as needed.
10 mg orally once daily.
None Documented
None Documented
The terminal elimination half-life is 7-9 hours in adults with normal renal function. This may be prolonged (up to 20-30 hours) in patients with severe renal impairment (CrCl <30 mL/min), necessitating dose adjustment.
Terminal elimination half-life: 12-18 hours (mean 14 hours). Clinically, this supports twice-daily dosing with steady-state achieved in ~3 days.
Renal excretion of unchanged drug accounts for 60-70% of the administered dose, with the remainder undergoing hepatic metabolism to inactive metabolites that are excreted renally. Fecal elimination is minimal (<5%).
Renal: ~70% unchanged; Fecal: ~25%; Biliary: <5%
Category C
Category C
Multivitamin/Mineral Supplement
Multivitamin/Mineral Supplement